Asston Pharmaceuticals IPO Subscribed 186.40 Times on Final Day

Asston Pharmaceuticals' initial public offering (IPO) has demonstrated exceptional investor demand through its third and final day of subscription, with Asston Pharmaceuticals' stock price set at ₹123 per share reflecting tremendous market reception. The ₹27.56 crore IPO surged dramatically to 186.40 times by 4:59:34 PM on day three, indicating extraordinary investor interest in this pharmaceutical exporter incorporated in 2019.

Asston Pharmaceuticals IPO non-institutional investors segment leads with phenomenal 353.10 times subscription, whilst individual investors demonstrate outstanding participation at 171.78 times and qualified institutional buyers show robust interest at 85.76 times, reflecting overwhelming investor confidence in this company.

Subscription Status of Asston Pharmaceuticals IPO:

Here are the subscription details for Asston Pharmaceuticals IPO as of Day 3 (July 11, 2025, 4:59:34 PM):

Key Highlights - Day 3: 

• Overall subscription reaching an outstanding 186.40 times, a massive surge from day two's 13.84 times
• NII segment leading with phenomenal demand at 353.10 times, dramatically increasing from day two's 19.67 times
• bNII category showing exceptional participation at 424.47 times, reflecting extraordinary high-net-worth investor appetite
• Individual investors demonstrating outstanding interest at 171.78 times, significantly jumping from day two's 16.66 times
• QIB segment showing robust participation at 85.76 times, substantially building from day two's 4.47 times
• sNII category displaying strong interest at 210.74 times, indicating broad-based HNI participation
• Final day witnessed extraordinary participation across all investor categories
• Total applications reached 79,586, indicating substantial investor participation for this SME IPO
• Cumulative bid amount reached ₹3,423.03 crores against the issue size of ₹27.56 crores

Asston Pharmaceuticals IPO - Day 2 Subscription at 13.84 Times

Key Highlights - Day 2:

• Overall subscription improving to 13.84 times from day one's 1.75 times
• NII segment demonstrating strong growth at 19.67 times, building momentum from day one's 0.66 times
• Individual investors showing solid improvement at 16.66 times, significantly increasing from day one's 1.22 times
• QIB segment showing steady progress at 4.47 times, building from day one's 3.51 times
• bNII category leading with 19.29 times, whilst sNII showed strong interest at 21.50 times

Asston Pharmaceuticals IPO - Day 1 Subscription at 1.75 Times

Key Highlights - Day 1:

• Overall subscription opening positively at 1.75 times, showing encouraging initial investor interest
• QIB segment leading early participation at 3.51 times, indicating institutional confidence
• Individual investors showing modest early interest at 1.22 times, reflecting measured retail sentiment
• NII segment demonstrating limited early interest at 0.66 times, reflecting cautious high-net-worth approach

About Asston Pharmaceuticals Limited

Incorporated in 2019, Asston Pharmaceuticals Limited is engaged in the business of pharmaceuticals, specialising in exporting healthcare products globally. The company offers a diverse range of products, including tablets, capsules, sachets, and syrups across various therapeutic categories such as analgesics, antibiotics, antifungals, and vitamins. The company manufactures pharmaceutical products for direct sales and on a contract manufacturing basis, working on a principle-to-principle approach with various marketers whilst maintaining FDA certification from both Central and State FDA, employing 46 permanent and 6 contractual personnel as of July 2025.